BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

AstraZeneca PLC (AZN)'s Brilinta Worse With High-Dose Aspirin in Analysis


6/29/2011 6:47:42 AM

A new study backs up a suggestion that high dosages of aspirin may interfere with AstraZeneca's heart drug Brilinta, offering a possible explanation for disappointing results from a trial among patients in North America. The potential multibillion dollar drug is already approved in 33 countries, but the prospects of a green light from U.S, regulators have been clouded by a trial that appeared to show it performed worse than rival drug Plavix. Experts have speculated that the lack of effect in U.S. patients might be due to the drug's interaction with aspirin, which is typically given in higher doses alongside treatments such as Plavix in the United States than in Europe.

Read at Reuters
Read at the heart.org
Read at Forbes
Read at Bloomberg

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES